Mediwheel <wellness@mediwheel.in>

Sun 3/3/2024 4:28 PM

To:PHC [MH-Ghaziabad] <phc.ghaziabad@manipalhospitals.com> Cc:customercare@mediwheel.in <customercare@mediwheel.in>



## 011-41195959 Email:wellness@mediwheel.in

Dear Manipal Hospitals.

Diagnostic/Hospital Location :NH-24 Hapur Road,Oppo. Bahmeta Village, Near Lancroft Golf Links Apartment, City: Ghaziabad

We regret to state that following request for Health check up appointment has been Re Scheduled by you. Please let us know if request had not been Re Schedule from your end. We will ask the user to make a fresh request for the same.

Booking Code : bobE52356

Appointment Date: 09-03-2024

Appointment Time: 8:00am-8:30am

Beneficiary Name : MR. SAHAI MANOJ KUMAR

Package Name

: Medi-Wheel Metro Full Body Health Checkup Male Above 40

Member Age

Member Relation

: Employee

Member Gender

: Male

Address of

NH-24 Hapur Road, Oppo. Bahmeta Village, Near Lancroft Golf Links

Diagnostic/Hospital Apartment

City

: Ghaziabad

State

: Uttar Pradesh

Pincode

: 201002

**Contact Details** 

: 9910525735

Email

: phc.ghaziabad@manipalhospitals.com

Please login to your account to confirm the same. Also you mail us for confirmation.

Adv. 2023-2024. Accolemi Mestificare Limited.







मनोज कुमार Manoj Kumar जन्म तिथि/ DOB: 25/01/1970 TO / MALE



**5124** 5686 5153

मेरा आधार, मेरी पहचान



पता: S/O फूल सहाय, 16, रईसपुर, गाजियाबाद, गाजियाबाद, उत्तर प्रदेश - 201002

Address: S/O Phool Sahai, 16, Raispur, Ghaziabad, Ghaziabad, Uttar Pradesh -201002







मस्त्रीय विकास महनान प्राधिकरण

P.O. Box No.1947, Bengaluru-560 001

help@uidai.gov.in www.uidai.gov.in



Court

# manipalhospitals



# LIFE'S ON TMT INVESTIGATION REPORT

Patient Name MR MANOJ KUMAR SAHAI

Location

: Ghaziabad

Age/Sex

: 54Year(s)/male

Visit No.

: V0000000001-GHZB

MRN No

MH010131750

Order Date

: 28/03/2024

Ref. Doctor : DR ABHISHEK SINGH

Report Date

: 28/03/2024

**Protocol** 

: Bruce

MPHR

: 166BPM

**Duration of exercise Reason for termination** 

: 7min 10sec

85% of MPHR

: 141BPM

Blood Pressure (mmHg) : Baseline BP : 110/90mmHg

: THR achieved

Peak HR Achieved : 166BPM % Target HR

: 100%

Peak BP

: 150/90mmHa

**METS** 

: 8.8METS

STAGE	TIME (min)	H.R (bpm)	BP (mmHg)	SYMPTOMS	ECG CHANGES	ARRHYTHMIA
PRE- EXC.	0:00	64	110/90	Nil	No ST changes seen	Nil
STAGE 1	3:00	104	120/90	Nil	No ST changes seen	Nil
STAGE 2	3:00	136	140/90	Nil	No ST changes seen	Nil
STAGE 3	1:10	166	150/90	Nil	0.5-1mm ST depression	Nil
RECOVERY	5:34	93	130/80	Nil	in inferolateral lead  No new ST changes seen	Nil

### **COMMENTS:**

- No ST changes in base line ECG.
- 0.5-1mm ST depression in inferolateral lead at peak stage.
- No ST changes in recovery.
- Normal chronotropic response.
- Normal blood pressure response.

### **IMPRESSION:**

Treadmill test is mildly positive for exercise induced reversible myocardial ischemia.

Dr. Bhupendra Singh

MD, DM (CARDIOLOGY), FACC Sr. Consultant Cardiology

Dr. Abhishek Singh

Dr. Sudhanshu Mishra

MD, DNB (CARDIOLOGY), MNAMS MD Sr.Consultant Cardiology

Cardiology Registrar

Manipal Hospital, Ghaziabad

NH - 24, Hapur Road, Ghaziabad, Uttar Pradesh - 201 002

P: 0120-3535353

Page 1 of 2

Manipal Health Enterprises Private Limited

CIN: U85110KA2003PTC033055

Regd. Off. The Annexe, #98/2, Rustom Bagh, Off. HAL Airport Road, Bengaluru - 560 017

P +91 80 4936 0300 E info@manihospitals.com www.manipalhospitals.com





NAME	, MANOJ KUMAR SAHAI	STUDY DATE	28/03/2024 9:49AM	
AGE / SEX	54 y / M	HOSPITAL NO.	MH010131750	
ACCESSION NO.	R7135268	MODALITY	US	1
REPORTED ON	28/03/2024 10:35AM	REFERRED BY	HEALTH CHECK MGD	

### **USG ABDOMEN & PELVIS**

### **FINDINGS**

LIVER: Liver is normal in size (measures 145 mm), shape and but shows raised echogenicity suggestive of grade I fatty changes.

SPLEEN: Spleen is normal in size (measures 90 mm), shape and echotexture. Rest normal.

PORTAL VEIN: Appears normal in size and measures 10 mm.

COMMON BILE DUCT: Appears normal in size and measures 3 mm.

IVC, HEPATIC VEINS: Normal. BILIARY SYSTEM: Normal.

GALL BLADDER: Gall bladder is well distended. Wall thickness is normal and lumen is echofree. Rest normal.

PANCREAS: Pancreas is normal in size, shape and echotexture. Rest normal.

KIDNEYS: Bilateral kidneys are normal in size, shape and echotexture. Cortico-medullary differentiation is

maintained. Rest normal.

Right Kidney: measures 111 x 46 mm. Renal concretion measuring 4 mm is seen in the mid pole of right kidney. A small control calcification measuring 3.0 mm is seen in the lower role of right kidney.

kidney. A small cortical calcification measuring 3.9 mm is seen in the lower pole of right kidney.

Left Kidney: measures 99 x 47 mm. A tiny renal concretion measuring 3.2 mm is seen in the mid pole of left kidney.

PELVI-CALYCEAL SYSTEMS: There is mild prominence of right renal pelvis.

NODES: Not enlarged. FLUID: Nil significant.

URINARY BLADDER: Urinary bladder is well distended. Wall thickness is normal and lumen is echofree. Rest

normal.

PROSTATE: Prostate is enlarged in size and measures approximately 30 mL in volume.

SEMINAL VESICLES: Normal.

BOWEL: Visualized bowel loops appear normal.

### **IMPRESSION**

Grade I fatty liver.
Bilateral renal concretions.
Minimal fullness of right pelvicalyceal system.
Prostatomegaly.

Recommend clinical correlation.

Dr. Prabhat Prakash Gupta MBBS, DNB, MNAMS

CONSULTANT RADIOLOGIST

\*\*\*\*\*End Of Report\*\*\*\*\*





NAME	, MANOJ KUMAR SAHAI	STUDY DATE	28/03/2024 9:10AM	
AGE / SEX	54 y / M	HOSPITAL NO.	MH010131750	
ACCESSION NO.	R7135267	MODALITY	CR	1
REPORTED ON	28/03/2024 9:17AM	REFERRED BY	HEALTH CHECK MGD	

XR- CHEST PA VIEW

FINDINGS:

LUNGS: Normal. TRACHEA: Normal. CARINA: Normal.

RIGHT AND LEFT MAIN BRONCHI: Normal.

PLEURA: Normal. HEART: Normal.

RIGHT HEART BORDER: Normal. LEFT HEART BORDER: Normal. PULMONARY BAY: Normal. PULMONARY HILA: Normal.

AORTA: Normal.

THORACIC SPINE: Normal.

OTHER VISUALIZED BONES: Normal. VISUALIZED SOFT TISSUES: Normal.

DIAPHRAGM: Normal.

VISUALIZED ABDOMEN: Normal. VISUALIZED NECK: Normal.

IMPRESSION:

-No significant abnormality seen.

Please correlate clinically

Dr. Prabhat Prakash Gupta MBBS, DNB, MNAMS

CONSULTANT RADIOLOGIST

\*\*\*\*\*End Of Report\*\*\*\*\*





Name

MANOJ KUMAR SAHAI

Age

54 Yr(s) Sex: Male

Registration No

MH010131750

Lab No

202403004061

**Patient Episode** 

H18000001996

**Collection Date:** 

28 Mar 2024 08:55

Referred By

HEALTH CHECK MGD

**Reporting Date:** 28 Mar 2024 12:08

**Receiving Date** 

28 Mar 2024 08:55 :

**BIOCHEMISTRY** 

TEST

RESULT

UNIT

**BIOLOGICAL REFERENCE INTERVAL** 

Specimen Type : Serum

THYROID PROFILE, Serum

T3 - Triiodothyronine (ELFA)

1.090

ng/ml ug/ dl [0.610-1.630]

T4 - Thyroxine (ELFA) Thyroid Stimulating Hormone 6.050 7.700 # µIU/mL [4.680 - 9.360][0.250-5.000]

### NOTE:

TSH stimulates the thyroid gland to produce the main thyroid hormones T3 and T4. In cases of hyperthyroidism TSH level is severely inhibited and may even be undetectable. In rare forms of high-origin hyperthyroidism, the TSH level is not reduced, since the negative-feedback control of the thyroid hormones has no effect.

In cases of primary hypothyroidism, TSH levels are always much higher than normal and thyroid hormone levels are low.

The TSH assay aids in diagnosing thyroid or hypophysial disorders.

The T4 assay aids in assessing thyroid function, which is characterized by a decrease in thyroxine levels in patients with hypothyroidism and an increase in patients with hyperthyroidism.

The test has been carried out in Fully Automated Immunoassay System VIDAS using ELFA (Enzyme Linked Fluorescence Assay) technology.

Page 1 of 3





Name

: MANOJ KUMAR SAHAI

Age

54 Yr(s) Sex: Male

**Registration No** 

MH010131750

Lab No

202403004061

Patient Episode

: H18000001996

**Collection Date:** 

28 Mar 2024 08:55

Referred By

: HEALTH CHECK MGD

**Reporting Date:** 28 Mar 2024 13:16

**Receiving Date** 

: 28 Mar 2024 08:55

### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Specimen Type : Serum

PROSTATE SPECIFIC ANTIGEN (PSA-Total): 2.240

ng/mL

[<3.500]

Method : ELFA

Note :1. This is a recommended test for detection of prostate cancer along with Digital Recta Examination (DRE) in males above 50 years of age

damage caused by BPH, prostatitis, or prostate cancer may increase circulating PSA levels.

- 2. False negative / positive results are observed in patients receiving mouse monoclonal antibodies for diagnosis or therapy
- 3. PSA levels may appear consistently elevated / depressed due to the interference by hetero antibodies & nonspecific protein binding
- 4. Immediate PSA testing following digital rectal examination, ejaculation, prostatic massag indwelling catheterization, and ultrasonography and needle biopsy of prostate is not recomme as they falsely elevate levels
- 5. PSA values regardless of levels should not be interpreted as absolute evidence of the pre or absence of disease. All values should be correlated with clinical findings and results of other investigations
- 6. Sites of Non prostatic PSA production are breast epithelium, salivary glands, peri urethral
  - & anal glands, cells of male urethra && breast mil
  - 7. Physiological decrease in PSA level by 18% has been observed in hospitalized / sedentary patients either due to supine position or suspended sexual activity

Recommended Testing Intervals

- \* Pre-operatively (Baseline)
- \* 2-4 days post-operatively
- \* Prior to discharge from hospital
- \* Monthly follow-up if levels are high or show a rising trend

Page 2 of 3





Name

MANOJ KUMAR SAHAI

Age

54 Yr(s) Sex :Male

**Registration No** 

MH010131750

Lab No

202403004061

**Patient Episode** 

H18000001996

**Collection Date:** 

28 Mar 2024 08:55

Referred By

HEALTH CHECK MGD

Reporting Date:

28 Mar 2024 13:24

**Receiving Date** 

: 28 Mar 2024 08:55

### **BLOOD BANK**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Blood Group & Rh Typing (Agglutination by gel/tube technique) Specimen-Blood

Blood Group & Rh typing

B Rh(D) Positive

### Technical note:

ABO grouping and Rh typing is done by cell and serum grouping by microplate / gel technique.

-----END OF REPORT-----

Page 3 of 3

### NOTE:

# - Abnormal Values

11







Name

: MANOJ KUMAR SAHAI

: MH010131750

Registration No **Patient Episode** 

: H18000001996

Referred By **Receiving Date** 

: HEALTH CHECK MGD

: 28 Mar 2024 08:55

Age

54 Yr(s) Sex: Male

Lab No

202403004061

**Collection Date:** 

28 Mar 2024 08:55

**Reporting Date:** 

28 Mar 2024 12:01

### **HAEMATOLOGY**

. / 1	TV:	0.7	63	THI
		BH .	-	

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

COMPLETE BLOOD COUNT (AUTOMATED)		SPECIMEN-EDTA Whole Bl	ood
RBC COUNT (IMPEDENCE) HEMOGLOBIN Method:cyanide free SLS-colorimet	<b>4.33 #</b> 14.3	millions/cumm g/dl	[ <b>4.50-5.50</b> ] [13.0-17.0]
HEMATOCRIT (CALCULATED)  MCV (DERIVED)  MCH (CALCULATED)  MCHC (CALCULATED)  RDW CV% (DERIVED)  Platelet count	43.3 100.0 33.0 # 33.0 14.7 #	% fL pg g/dl % x 10 <sup>3</sup> cells/cumm	[40.0-50.0] [83.0-101.0] <b>[25.0-32.0]</b> [31.5-34.5] <b>[11.6-14.0]</b> [150-410]
Method: Electrical Impedance			[130-410]
MPV (DERIVED)  WBC COUNT (TC) (IMPEDENCE)  DIFFERENTIAL COUNT  (VCS TECHNOLOGY/MICROSCOPY)	13.70 4.35	fL x 10 <sup>3</sup> cells/cumm	[4.00-10.00]
Neutrophils Lymphocytes Monocytes Eosinophils Basophils	43.0 40.0 8.0 <b>9.0</b> #	00 00 00 00 00 00	[40.0-80.0] [20.0-40.0] [2.0-10.0] [1.0-6.0] [0.0-2.0]
ESR	5.0	mm/1sthour	[0.0-

Page1 of 8







: MANOJ KUMAR SAHAI

Name : MH010131750 Registration No

: H18000001996 Patient Episode

: HEALTH CHECK MGD Referred By : 28 Mar 2024 10:01

**Receiving Date** 

54 Yr(s) Sex :Male Age

202403004061 Lab No

28 Mar 2024 10:01 Collection Date:

28 Mar 2024 11:59 Reporting Date:

## CLINICAL PATHOLOGY

# ROUTINE URINE ANALYSIS (Semi Automated) Specimen-Urine

ROUTINE URINE		(Pale Yellow - Yellow)
MACROSCOPIC DESCRIPTION Colour	PALE YELLOW CLEAR 5.0	(4.6-8.0) (1.003-1.035)
Appearance	1 010	22

Reaction[pH] 1.010 Specific Gravity

(NEGATIVE) CHEMICAL EXAMINATION Negative (NIL) Protein/Albumin (NEGATIVE) NIL Negative (NORMAL) Glucose Ketone Bodies Normal

Urobilinogen

MICROSCOPIC EXAMINATION (Au	itomated/Ma	anual)	(0-5/hpf)
MICROSCOPIC EXAMINATION	2-3/hp	I	(0-2/hpf)
Pus Cells	NIL		
-200	0 - 1	/hpf	
Epithelial Cells	NIL		W m
DD -			38

CASTS NIL Crystals NIL NIL Bacteria OTHERS

Page 2 of 8







ivear Lanucrait Golflinks, Ghaziabad - 201002 Ph. +91 120 353 5353, M. 88609 45566 www.manipalhospitals.com

Name

: MANOJ KUMAR SAHAI

: MH010131750

**Registration No Patient Episode** 

: H18000001996

Referred By **Receiving Date**  : HEALTH CHECK MGD

: 28 Mar 2024 08:55

Age

54 Yr(s) Sex: Male

Lab No

202403004061

**Collection Date:** 

28 Mar 2024 08:55

Reporting Date:

28 Mar 2024 13:16

### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

Glycosylated Hemoglobin

Specimen: EDTA

HbAlc (Glycosylated Hemoglobin)

5.1

[0.0-5.6]

Method: HPLC

As per American Diabetes Association (ADA HbAlc in % Non diabetic adults >= 18 years <5.7

Prediabetes (At Risk )5.7-6.4 Diagnosing Diabetes >= 6.5

Estimated Average Glucose (eAG)

100

mg/dl

Comments : HbA1c provides an index of average blood glucose levels over the past 8-12 weeks and is a much better indicator of long term glycemic control.

### Serum LIPID PROFILE

Serum TOTAL CHOLESTEROL Method:Oxidase,esterase, peroxide	205 #	mg/dl	[<200] Moderate risk:200-239
TRIGLYCERIDES (GPO/POD)	168 #	mg/dl	High risk:>240
		,	Borderline high:151-199 High: 200 - 499
HDL- CHOLESTEROL Method: Enzymatic Immunoimhibition	56	mg/dl	Very high:>500 [35-65]
VLDL- CHOLESTEROL (Calculated) CHOLESTEROL, LDL, CALCULATED	34 115.0	mg/dl mg/dl	[0-35] [<120.0]
			Near/

Above optimal-100-129

Borderline High: 130-159 High Risk: 160-189

Page 3 of 8







Name

: MANOJ KUMAR SAHAI

Registration No

: MH010131750

**Patient Episode** 

: H18000001996

Referred By

: HEALTH CHECK MGD

: 28 Mar 2024 08:55 **Receiving Date** 

Age

54 Yr(s) Sex :Male

Lab No

202403004061

**Collection Date:** 

28 Mar 2024 08:55

Reporting Date:

28 Mar 2024 10:02

### **BIOCHEMISTRY**

TEST T.Chol/HDL.Chol ratio(Calculated	RESULT	3.7	UNIT	<pre>8 SIOLOGICAL REFERENCE INTERVAL</pre>
1.0101/1122				>6 High Risk
LDL.CHOL/HDL.CHOL Ratio(Calculat	.ed)	2.1	er er	<pre>&lt;3 Optimal 3-4 Borderline &gt;6 High Risk</pre>

### Note:

Reference ranges based on ATP III Classifications.

Lipid profile is a panel of blood tests that serves as initial broad medical screening tool for abnormalities in lipids, the results of this tests can identify certain genetic diseases and determine approximate risks for cardiovascular disease, certain forms of pancreatitis and other diseases

## KIDNEY PROFILE

Specimen: Serum	19.9	mg/dl	[15.0-40.0]
Method: GLDH, Kinatic assay	9.3	mg/dl	[8.0-20.0]
BUN, BLOOD UREA NITROGEN Method: Calculated	0.88	mg/dl	[0.70-1.20]
CREATININE, SERUM Method: Jaffe rate-IDMS Standardization URIC ACID Method:uricase PAP	7.0	mg/dl	[4.0-8.5]
Method: ulicase iii			
OTDUM	136.20	mmol/L	[136.00-144.00]
SODIUM, SERUM POTASSIUM, SERUM SERUM CHLORIDE	4.17 102.6	mmol/L	[3.60-5.10] [101.0-111.0]
Method: ISE Indirect			Page 4 of 8

Page 4 of 8







Name

: MANOJ KUMAR SAHAI

Age

54 Yr(s) Sex :Male

Registration No

: MH010131750

Lab No

202403004061

**Patient Episode** 

: H18000001996

**Collection Date:** 

28 Mar 2024 08:55

Referred By

: HEALTH CHECK MGD

Reporting Date:

28 Mar 2024 10:02

**Receiving Date** 

: 28 Mar 2024 08:55

### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

eGFR (calculated)

97.4

ml/min/1.73sq.m

[>60.0]

Technical Note eGFR which is primarily based on Serum Creatinine is a derivation of CKD-EPI 2009 equation normalized to1.73 sq.m BSA and is not applicable to individuals below 18 years. eGFR tends to be less accurate when Serum Creatinine estimation is indeterminate e.g. patients at extremes of muscle mass, on unusual diets etc. and samples with severe Hemolysis Icterus / Lipemia.

### LIVER FUNCTION TEST

		/ -17	[0.30-1.20]
BILIRUBIN - TOTAL Method: D P D	1.01	mg/dl	[0.30-1.20]
BILIRUBIN - DIRECT Method: DPD	0.18	mg/dl	[0.00-0.30]
INDIRECT BILIRUBIN (SERUM) Method: Calculation	0.83	mg/dl	[0.10-0.90]
TOTAL PROTEINS (SERUM)  Method: BIURET	6.80	gm/dl	[6.60-8.70]
ALBUMIN (SERUM) Method: BCG	4.17	g/dl	[3.50-5.20]
GLOBULINS (SERUM) Method: Calculation	2.60	gm/dl	[1.80-3.40]
PROTEIN SERUM (A-G) RATIO Method: Calculation	1.59		[1.00-2.50]
AST(SGOT) (SERUM) Method: IFCC W/O P5P	25.00	U/L	[0.00-40.00]

Page 5 of 8







Ph. +91 120 353 5353, M. 88609 45566 www.manipalhospitals.com

Name

: MANOJ KUMAR SAHAI

Age

54 Yr(s) Sex :Male

**Registration No** 

: MH010131750

Lab No

202403004061

Patient Episode

: H18000001996

**Collection Date:** 

28 Mar 2024 08:55

Referred By

: HEALTH CHECK MGD

Reporting Date:

28 Mar 2024 10:03

**Receiving Date** 

: 28 Mar 2024 08:55

### **BIOCHEMISTRY**

TEST	RESULT	UNIT	BIOLOGICAL REFERENCE INTERV	AL
ALT (SGPT) (SERUM)	19.20	U/L	[17.00-63.00]	
Method: IFCC W/O P5P				
Serum Alkaline Phosphatase Method: AMP BUFFER IFCC)	68.0	IU/L	[32.0-91.0]	
GGT	15.0	Ū/	(L [7.0-50.0]	

Liver function test aids in diagnosis of various pre hepatic, hepatic and post hepatic causes of dysfunction like hemolytic anemia's, viral and alcoholic hepatitis and cholestasis of obstructive causes.

The test encompasses hepatic excretory, synthetic function and also hepatic parenchymal cell damage. LFT helps in evaluating severity, monitoring therapy and assessing prognosis of liver disease and dysfunction.

Page 6 of 8

-----END OF REPORT------







medi Lanucian Gominis,

Name

: MANOJ KUMAR SAHAI

Age

54 Yr(s) Sex: Male

**Registration No** 

: MH010131750

Lab No

202403004062

**Patient Episode** 

: H18000001996

**Collection Date:** 28 Mar 2024 08:55

Referred By

: HEALTH CHECK MGD

**Reporting Date:** 

28 Mar 2024 10:22

**Receiving Date** 

: 28 Mar 2024 08:55

### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

### GLUCOSE-Fasting

Specimen: Plasma GLUCOSE, FASTING (F) Method: Hexokinase

92.0

mg/dl

[70.0 - 110.0]

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and so that no glucose is excreted in the urine.

Increased in Diabetes mellitus, Cushing's syndrome (10-15%), chronic pancreatitis (30%). Drugs corticosteroids, phenytoin, estrogen, thiazides

Decreased in Pancreatic islet cell disease with increased insulin, insulinoma, adrenocortica insufficiency, hypopituitarism, diffuse liver disease, malignancy (adrenocortical, stomach, fibro sarcoma), infant of a diabetic mother enzyme deficiency diseases (e.g.galactosemia),

insulin, ethanol, propranolol, sulfonylureas, tobutamide, and other oral hypoglycemic agents.

Page 7 of 8

-----END OF REPORT-----







Name

: MANOJ KUMAR SAHAI

Registration No

: MH010131750

**Patient Episode** 

: H18000001996

Referred By

: HEALTH CHECK MGD

**Receiving Date** 

: 28 Mar 2024 14:39

Age

54 Yr(s) Sex :Male

Lab No

202403004063

**Collection Date:** 

28 Mar 2024 14:39

**Reporting Date:** 

28 Mar 2024 15:32

### **BIOCHEMISTRY**

TEST

RESULT

UNIT

BIOLOGICAL REFERENCE INTERVAL

### PLASMA GLUCOSE

Specimen:Plasma

GLUCOSE, POST PRANDIAL (PP), 2 HOURS

121.0

mg/dl

[80.0-140.0]

Method: Hexokinase

Note:

Conditions which can lead to lower postprandial glucose levels as compared to fasting glucose are excessive insulin release, rapid gastric emptying,

brisk glucose absorption , post exercise

Page 8 of 8

-----END OF REPORT-----